Pharmacological concentrations of the HMG-CoA reductase inhibitor lovastatin decrease the formation of the Alzheimer beta-amyloid peptide in vitro and in patients.

Frontiers in Bioscience : a Journal and Virtual Library
J D BuxbaumL T Friedhoff

Abstract

Epidemiological studies demonstrate that hypercholesterolemia is a risk factor for Alzheimer's disease (AD). As the generation and accumulation of the beta-amyloid peptide (Abeta) in the brain appears to be significant for the initiation and progression of AD, it is possible that cholesterol levels regulate Abeta formation and/or clearance. To test the effects of altering cholesterol on Abeta formation, we incubated cells with or without lovastatin acid, the active metabolite of the HMG-CoA reductase inhibitor lovastatin, and measured the fraction of Abeta formed from its precursor under each condition. We observed that treatment with lovastatin acid led to a profound decrease in the levels of Abeta formed. This effect was observed at concentrations of 0.05-5 microM, ranges where this compound is effective at inhibiting HMG-CoA reductase. To examine the effects of lovastatin on Abeta in vivo, human subjects who had elevated low-density lipoprotein cholesterol were treated during a double-blind, randomized study with 10-60-mg once-daily doses of a controlled-release formulation of lovastatin, or matching placebo. Serum Abeta concentrations were measured before and after up to 3 months of treatment. Mean and median changes from b...Continue Reading

Citations

Sep 23, 2008·Molecular Diagnosis & Therapy·Anders Lönneborg
Dec 17, 2003·Clinical Biochemistry·Sultan DarveshKenneth Rockwood
Jul 31, 2013·Neuropharmacology·R AnandAbbas Ali Mahdi
Aug 2, 2007·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Yan ZhouKumar Sambamurti
Feb 18, 2005·NeuroRx : the Journal of the American Society for Experimental NeuroTherapeutics·Michael C Irizarry
Aug 16, 2003·Proceedings of the National Academy of Sciences of the United States of America·D Larry Sparks, Bernard G Schreurs
Mar 22, 2006·The Consultant Pharmacist : the Journal of the American Society of Consultant Pharmacists·Edna Patatanian, Mark A Gales
Dec 19, 2015·Critical Reviews in Clinical Laboratory Sciences·Menuka Pallebage-GamarallageJohn Mamo
Apr 14, 2006·Molecular Membrane Biology·Joanna M CordyAnthony J Turner
May 22, 2004·Journal of Clinical Pharmacy and Therapeutics·J Caballero, M Nahata
Oct 19, 2006·Journal of Biomedicine & Biotechnology·Leonel RojoRicardo B Maccioni
Apr 22, 2010·Experimental Neurology·Qing WangMidori A Yenari
Nov 18, 2015·Evidence-based Complementary and Alternative Medicine : ECAM·Doaa A GhareebMaha A El-Demellawy
Sep 6, 2005·Clinica Chimica Acta; International Journal of Clinical Chemistry·Vincenzo SolfrizziFrancesco Panza
Jan 16, 2007·Trends in Pharmacological Sciences·Daniel L AlkonThomas J Nelson
Sep 3, 2003·Journal of Lipid Research·Neelima B Chauhan
Sep 21, 2018·The Australian and New Zealand Journal of Psychiatry·Gerwyn MorrisMichael Berk
Aug 9, 2005·The Journal of Biological Chemistry·Andrew CordleGary Landreth

❮ Previous
Next ❯

Related Concepts

Related Feeds

Alzheimer's Disease: Amyloid Beta

Alzheimer's disease is a neurodegenerative disease associated with the accumulation of amyloid plaques in the brain; these plaques are comprised of amyloid beta deposits. Here is the latest research in this field.

Alzheimer's Disease: APP

Amyloid precursor protein (APP) proteolysis is critical for the development of Alzheimer's disease, a neurodegenerative disease associated with accumulation of amyloid plaques in the brain. Here is the latest research on APP and Alzheimer's disease.